Kursprognose für Liminatus Pharma Inc (LIMN)LIMNLiminatus Pharma Inc

Alphio's LIMN stock price prediction model matches the current Liminatus Pharma Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $2.47 (-1.33%). The 1-week path is $2.56 (+2.27%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Liminatus Pharma Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $2.50, which is 92.20% lower than its year-to-date performance. The RSI is at 29.815, indicating that the stock is oversold, but this is not sufficient to justify a buy given the overall financial health. The company has a forward P/E ratio of 0, suggesting no earnings growth expectations, and a gross margin of 0%, indicating no profitability. The main risk is the company's high debt-to-equity ratio of 479.85%, which poses a significant financial risk.

Liminatus Pharma Inc (LIMN) last closed at $2.5, losing -4.94%. These facts feed the 1-day and 1-week LIMN price prediction above.